AMGEN INC is 86.7x more valuable than BIOCRYST PHARMACEUTICALS INC by market capitalization ($191.70 B vs $2.21 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BCRX | AMGN |
|---|---|---|
| Market cap | $2.21 B | $191.70 B |
| US-listed rank | #2044 | #79 |
| Revenue (latest FY) | $874.84M | $36.75B |
| Net income (latest FY) | $263.86M | $7.71B |
| Net margin | 30.2% | 21.0% |
| P/E (trailing FY) | 8.4 | 24.9 |
| SEC filings | 1,935 | 1,011 |
AMGEN INC is 86.7x more valuable than BIOCRYST PHARMACEUTICALS INC by market capitalization ($191.70 B vs $2.21 B).
In their latest fiscal years, BIOCRYST PHARMACEUTICALS INC reported $874.84M in revenue while AMGEN INC reported $36.75B.
Full pages: BIOCRYST PHARMACEUTICALS INC and AMGEN INC, or browse the full rankings.